Although imatinib mesylate has revolutionized the treatment of chronic myeloid leukaemia (CML), resistance to the drug, manifesting as relapse after an initial response or persistence of disease, ...

Zoledronate is a biophosphonate, a drug used to strengthen bones and reduce the risk of osteoporosis-related bone fractures. It is well-absorbed into the bones, so it only needs to be administered ...

Following an infusion of zoledronate acid in low-risk postmenopausal women, fracture risk reduction emerged only 5-10 years later in a placebo-controlled trial. By year 10, those who received a single ...

The researchers found that 6.3, 6.6, and 11.1% of the zoledronate-zoledronate, zoledronate-placebo, and placebo-placebo groups, respectively, had a new morphometric fracture at follow-up. HealthDay ...

Giving zoledronate every 18 months for 6 years reduced the risk of fragility fractures—both vertebral and nonvertebral—in older women with hip bone mineral density indicating osteopenia, a ...

Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Women who went 5 years between zoledronate infusions had ...

Bisphosphonates prevent fractures in patients with osteoporosis, but their efficacy in women with osteopenia is unknown. Most fractures in postmenopausal women occur in those with osteopenia, so ...

Intravenous zoledronate (Reclast) administered once every 5 years reduced the incidence of morphometric vertebral fractures in early postmenopausal women, a randomized trial showed. Over 10 years of ...

Please provide your email address to receive an email when new articles are posted on . “The need to establish treatment efficacy in osteopenia has become more pressing, given the clinical trend to ...

Women in early menopause treated with zoledronate in just two infusions, 5 years apart, show a significantly reduced risk of sustaining a vertebral fracture and better maintenance of bone mineral ...

BACKGROUND: Intravenous zoledronate 5 mg annually reduces fracture risk, and 5 mg every 2 years prevents bone loss, but the optimal dosing regimens for these indications are uncertain. METHODS: We ...